ASH 2023 – sense and serendipity in Dizal's Jackpot win
Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.
ASH 2023 – a new EZ battle shapes up
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.
ASH 2023 – the search for a better Ayvakit
Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.
ASH 2023 – J&J makes menin a three-horse race
But JNJ-75276617 still has much to prove.
A triplet of Keytruda failures
Merck sees clinical setbacks in Keylynk-008, Leap-001 and Keyvibe-002.
